Merck & Co. Inc. has announced that the U.S. Centers for Disease Control and Prevention $(CDC)$ Advisory Committee on Immunization Practices (ACIP) has voted to recommend ENFLONSIA™ (clesrovimab-cfor) for preventing respiratory syncytial virus (RSV) lower respiratory tract disease in infants younger than 8 months who are born during or entering their first RSV season. The recommendation includes ENFLONSIA in the Vaccines for Children Program, ensuring broader access for infants. This follows the U.S. Food and Drug Administration's approval of ENFLONSIA based on clinical trials. Merck plans to start ordering in July 2025, with deliveries before the 2025-2026 RSV season. The ACIP's recommendation is provisional, pending final approval by the CDC Director or Health and Human Services Secretary.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。